Tackling inflammation in the gut: the role of ‘unconventional’ immune cells
Peer-Reviewed Publication
Updates every hour. Last Updated: 8-Oct-2025 08:10 ET (8-Oct-2025 12:10 GMT/UTC)
Immune cells called double negative T cells are abundant in the intestine but have been poorly understood till date. In a recent study, researchers from Institute of Science Tokyo report that these cells actually have an indispensable role in suppressing intestinal inflammation. Through cutting-edge microscopy that allows live imaging, the movement and functioning of these cells were visualized for the first time, providing insights into conditions such as Crohn’s disease.
Phospholipids, essential components of cell membranes, are increasingly recognized for their active roles in regulating innate immunity and inflammation. A new review is published to outline how phospholipid metabolism shapes immune cell behavior, influences the outcome of host defense and tissue homeostasis. The authors also discuss how dysregulation of phospholipid metabolism contributes to inflammatory diseases, such as autoimmune diseases, cardiovascular diseases and cancers, and highlight the potential strategies of restoring phospholipid homeostasis for disease treatment.
Two distinct stem cell lineages that drive tooth root and alveolar bone formation have been identified by researchers from Science Tokyo. Using genetically modified mice and lineage-tracing techniques, the team shed light on the cell signaling mechanisms guiding differentiation in stem cells in the developing teeth, offering key insights for future regenerative dental therapies.
Certain nutrients in food can trigger a mild stress response in nematodes. But instead of making them sick, this actually helps them stay healthier as they age, according to researchers at the University of Basel, Switzerland.
A research team from the USC Norris Comprehensive Cancer Center, in collaboration with City of Hope, has found a promising way to adapt CAR T cell therapy so that it can fight solid tumors. The researchers engineered CAR T cells to produce a fusion of two proteins: interleukin 12 (IL-12) cytokine, which boosts immune activity, and a programmed death-ligand 1 (PD-L1) blocker, an immune checkpoint inhibitor that prevents cancer cells from turning off the immune attack. In mouse models of prostate and ovarian cancer, the modified CAR T cells launched a localized attack, shrinking the tumor without causing toxicity in other parts of the body. The results were just published in the journal Nature Biomedical Engineering. The approach enhanced the ability of T cells to penetrate tumors and made the surrounding environment less hostile. It was also safe, with minimal toxicity elsewhere in the body, making it an attractive therapy to translate to patients.